

**Appendix Table 1. Serum panels used in the study**

serum panel	Ghana 1	Ghana 2	Madagascar	Nigeria	Colombia	Lao PDR	Germany
number	29	50	79	40	40	20	75
sampling year	2010 - 2012	2014 - 2015	2010	2018	2014	2014	2007 - 2015
sampling site	Agogo	Agogo	Manakara/ Tsiroanomandidy	Irrua	Valledupar	Savannakhet	Hamburg
sex m/f (n (%))	17/12 (59/41)	25/25 (50/50)	0/79 (0/100)	24/16 (60/40)	17/23 (43/57)	3/17 (15/85)	not available
age (median, IQR)	16 (7 – 23)	7 (6 – 9)	21 (18 – 29)	34 (7 – 85)*	23 (21 – 25)	48 (45 – 53)	not available
remarks	hospitalized febrile patients; 7 (24 %) presenting with parasitemia ( <i>Plasmodium spp.</i> )	symptom-free children; 24 (48 %) presenting with parasitemia ( <i>Plasmodium spp.</i> )	symptom-free pregnant women; 3 (4 %) presenting with parasitemia ( <i>Plasmodium spp.</i> )	symptom-free donors	symptom-free donors	symptom-free donors	symptom-free donors

M: male, f: female, IQR: interquartile range.

All studies complied with the Declaration of Helsinki. Written informed consent was obtained from all individuals or, in case of minors, from parents or legal guardians before enrollment. Data privacy protection was guaranteed by anonymization of samples. Collection of samples has been approved by the Ethics Committees of the Kwame Nkrumah University of Science and Technology, Kumasi/Ghana (CHRPE/AP/427/13 and CHRPE/101/09), the Comité d'éthique de la Vice Primature Chargée de la Santé Publique, Antananarivo/Madagascar (No. 051-CE/MINSAN), the Irrua Specialist Teaching Hospital, Irrua/Nigeria (ISTH/HREC/20171019/28), the Hospital Rosario Pumarejo de Lopez of Valledupar/Colombia, the Lao People's Democratic Republic (No. 030/NECHR), and the Medical Association Hamburg/Germany (No. PV4608)

\*n=39 (age information not available for one donor)

**Appendix Table 2. Commercially available ELISA kits used in the study**

	<b>Euroimmun Anti-SARS-CoV-2-NCP-ELISA IgG</b>	<b>Euroimmun Anti-SARS-CoV-2-ELISA IgG</b>	<b>EDJ™ Novel Coronavirus COVID-19 IgG ELISA kit</b>	<b>Mikrogen recomWell SARS-CoV-2 IgG</b>	<b>Wantai SARS-CoV-2 Ab ELISA</b>
<b>manufacturer</b>	Euroimmun AG Lübeck, Germany	Euroimmun AG Lübeck, Germany	Epitope Diagnostics, Inc. San Diego, US	Mikrogen GmbH Neuried, Germany	Wantai BioPharm Ltd. Beijing, China
<b>status</b>	CE-IVD	CE-IVD, FDA EUA	CE-IVD	CE-IVD	CE-IVD
<b>antibody isotype</b>	IgG	IgG	IgG	IgG	total antibody
<b>test format</b>	96 well microplate	96 well microplate	96 well microplate	96 well microplate	96 well microplate
<b>test principle</b>	indirect ELISA	indirect ELISA	indirect ELISA	indirect ELISA	antigen sandwich
<b>antigen</b>	NCP (modified)	spike (S1 domain)	NCP (recombinant)	NCP (recombinant)	not specified in IFU; spike RBD (4)
<b>sample dilution</b>	1:101	1:101	1:101	1:101	none (undiluted serum)
<b>interpretation index value (iv)</b>	negative: $iv < 0.8$ borderline: $0.8 \leq iv < 1.1$ positive: $iv \geq 1.1$	negative: $iv < 0.8$ borderline: $0.8 \leq iv < 1.1$ positive: $iv \geq 1.1$	negative: $iv \leq 0.9$ borderline: $0.9 < iv < 1.1$ positive: $iv \geq 1.1$	negative: $iv < 1.0$ borderline: $1.0 \leq iv < 1.2$ positive: $iv \geq 1.2$	negative: $iv < 1$ borderline: $0.9 \leq iv < 1.1$ positive: $iv \geq 1$
<b>references</b>	(7)	(4-8)	(5,6)	(5)	(4, 7, 8)


CE: Conformité Européenne, IVD: *in vitro* diagnostics; FDA: Food and Drug Administration; EUA: Emergency Use Authorization; NCP: nucleocapsid protein; RBD: receptor binding domain; IFU: Instructions for Use

**Appendix Table 3. SARS-CoV-2 IgG ELISA specificities for donor subgroups with different health status**

				Euroimmun Anti-SARS-CoV-2-NCP-ELISA IgG	Euroimmun Anti-SARS-CoV-2-ELISA IgG	EDI™ Novel Coronavirus COVID-19 IgG ELISA kit	Mikrogen recomWell SARS-CoV-2 IgsG									
Ghana (n=79)	parasitemic (n=31)	pos	bl	neg	5	1	25	3	1	27	6	6	19	1	1	29
		specificity (95% CI)			83.9 (66.9 – 93.4)			90.3 (74.3 – 97.4)			80.6 (63.3 – 91.2)			96.8 (82.4 – 100.0)		
	not parasitemic (n=48)	pos	bl	neg	4	2	42	4	2	42	10	3	35	4	1	43
		specificity (95% CI)			91.7 (79.9 – 97.2)			91.7 (79.9 – 97.2)			79.2 (65.6 – 88.5)			91.7 (79.9 – 97.2)		
Ghana (n=79)	febrile (n=29)	pos	bl	neg	2	0	27	2	3	24	10	4	15	2	0	27
		specificity (95% CI)			93.1 (77.0 – 99.1)			93.1 (77.0 – 99.1)			65.5 (47.3 – 80.1)			93.1 (77.0 – 99.1)		
	symptom-free (n=50)	pos	bl	neg	7	3	40	5	0	45	6	5	39	3	2	45
		specificity (95% CI)			86.0 (73.5 – 93.4)			90.0 (78.2 – 96.1)			88.0 (75.8 – 94.7)			94.0 (83.2 – 98.6)		

pos/bl/neg: number of samples rated as positive (pos), borderline (bl), and negative (neg) by the respective test. CI: confidence interval. For calculation of specificities, both negative and borderline results were classified as “not positive”.

# Appendix Figure 1



**Appendix Figure 1. Wantai SARS-CoV-2 Ab ELISA results.** The complete Nigerian serum panel (n=40) as well as subsets of the Ghanaian (n=49) and the Madagascar (n=36) serum panels were analyzed using the Wantai SARS-CoV-2 Ab ELISA (A). Results obtained for the respective panel/subsets with (B) the Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA, (C) the Euroimmun Anti-SARS-CoV-2 IgG ELISA, (D) the EDI Novel Coronavirus COVID-19 IgG ELISA, and (E) the Mikrogen *recomWell* SARS-CoV-2 IgG ELISA are displayed for comparison.